AstraZeneca plc's latest pair of deals - the acquisition of Spirogen Ltd. and a partnership with ADC Therapeutics S.a.r.l. - gives the pharma's MedImmune LLC biologics unit all the tools it needs for antibody-drug conjugates.

ADCs are one of MedImmune's two primary focus areas in cancer. The other area, immunotherapy, was the driver of MedImmune's acquisition of Amplimmune Inc. for $225 million up front and up to $275 million in milestones.